Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Bayer develops compounds for neurodegenerative disorders

Dec. 19, 1997

Animal study indicates potential of GAT inhibitors for anxiety

Dec. 18, 1997

Behavioral effects of novel mGluR agonist in rats

Dec. 18, 1997

Italian launch for Alzheimer's disease treatment

Dec. 18, 1997

Naratriptan acts through 5-HT1B/1D receptors and accesses the CNS

Dec. 18, 1997

Oral morphine effective for management of sickle cell pain in children

Dec. 16, 1997

CerAxon submitted for approval in U.S.

Dec. 16, 1997

5-HT receptor (ant)agonists from Pfizer

Dec. 16, 1997

Migranal Nasal Spray approved by FDA

Dec. 15, 1997

Bupropion: drug of choice for depression in males with erectile dysfunction?

Dec. 15, 1997

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 10, 2025
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...
Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology
BioWorld
About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...